Table 1.
Clinical trials with anti-EGFR monoclonal antibodies in postprogression treatment.
| Study | No. of patients | Design | Treatment | Primary end point | Results | p |
|---|---|---|---|---|---|---|
| BOND [19] | 329 | Phase 3, open-label, RCT | C-mab versus C-mab + irinotecan | ORR | 10.8% versus 22.9% | 0.007 |
|
| ||||||
| CO17 [20] | 572 | Phase 3, RCT | BSC versus C-mab | OS | HR, 0.77; 95% CI, 0.64–0.92 | 0.005 |
|
| ||||||
| EPIC [21] | 1298 | Phase 3, open-label, RCT | Irinotecan versus C-mab + irinotecan | OS | HR, 0.975; 95% CI, 0.85–1.11 | 0.71 |
|
| ||||||
| Van Cutsem et al. [22] | 463 | Phase III, open-label, RCT | BSC versus P-mab + BSC | PFS | HR, 0.54; 95% CI, 0.44–0.66 | <0.0001 |
|
| ||||||
| Peeters et al. [23] | 1186 | Phase III, open-label, RCT | FOLFIRI versus P-mab + FOLFIRI | PFS | HR, 0.73; 95% CI, 0.59–0.9 | 0.004 |
| OS | HR, 0.85; 95% CI, 0.7–1.04 | 0.12 | ||||
|
| ||||||
| PICCOLO [26] | 460 | Phase III, open-label, RCT | Irinotecan versus P-mab + irinotecan | OS | HR, 1.01; 95% CI, 0.83–1.23 | 0.91 |
EGFR: epidermal growth factor receptor; No.: number; RCT: randomized controlled trial; pt: patient; C-mab: cetuximab; ORR: objective response rate; BSC: best supportive care; OS: overall survival; HR: hazard ratio; P-mab: panitumumab; PFS: progression-free survival.